AI-based Echocardiographic Quantification in Heart Failure
NCT ID: NCT07010952
Last Updated: 2025-06-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
3000 participants
OBSERVATIONAL
2025-07-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Simply diagnosing HFrEF requires an LVEF of less than 40%. Diagnosing HFpEF poses significant clinical challenges because no single tool or method can reliably confirm the condition or predict associated hospitalizations. Consequently, diagnosis depends heavily on physician judgment, requiring the synthesis of considerable clinical data and information. Recognizing the heterogeneity of the HFpEF phenotype, phenomapping integrates comprehensive data (clinical history, physiological measurements, biomarkers, ECG, echocardiographic parameters) to stratify patients into distinct subtypes, thereby optimizing classification for improved prognostic prediction. It can be seen from this that HF will rely heavily on artificial intelligence in the future to assist in patient data management and classification diagnosis and further develop clinical prediction models. This research project will implement a multi-center design to collect ultrasound images from patients with heart failure and perform relevant analyses using artificial intelligence.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Feasibility of AI-based Heart Function Prediction Model Using CXR
NCT04996381
Safety and Efficacy Study of AI LVEF
NCT05140642
A Multi-Center Study of Detection of Low Ventricular Ejection Fraction
NCT04963218
Prospective Evaluation of AI-ECG for SHD Detection
NCT07057466
External Validation of Artificial Intelligence-enabled Electrocardiography (AI-ECG) for the Detection of Left Ventricular Dysfunction (LVD)
NCT07038018
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Adult heart failure cohort with comprehensive echocardiographic imaging for AI-driven HF phenotyping
We will analyze a prospective, multicenter cohort of adult patients (≥18 years) admitted for acute or chronic heart failure at three tertiary hospitals between January 2021 and December 2023. Participants were stratified by index-echocardiographic left ventricular ejection fraction (LVEF): 1. HFpEF group: LVEF ≥ 50%, typical HF signs/symptoms, and objective evidence of diastolic dysfunction. 2. HFrEF group: LVEF \< 40%, consistent with guideline-defined systolic HF. Patients with mid-range LVEF (40-49%), significant valvular disease, congenital heart disease, or inadequate image quality were excluded. For every enrollee, complete transthoracic echocardiography was performed within 48 h of admission. Raw DICOM cine loops (parasternal long/short axis, apical 2-/3-/4-chamber, Doppler, and tissue Doppler views) were archived. Standardized hemodynamic and biomarker profiles, 12-lead ECGs, and comprehensive clinical data will be collected.
AI-based image analysis
AI-based imaging analysis
AI-based imaging analysis
AI-based imaging analysis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AI-based image analysis
AI-based imaging analysis
AI-based imaging analysis
AI-based imaging analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Admission for acute or chronic heart failure between January 1, 2017, and April 30, 2024.
3. Transthoracic echocardiography completed ≤ 48 h after admission with diagnostic-quality DICOM cine loops (parasternal long/short axis and apical 2-/3-/4-chamber views plus Doppler and tissue Doppler).
4. Meets one of the two predefined phenotypes:
* HFpEF: LVEF ≥ 50 % + typical HF signs/symptoms + objective diastolic dysfunction.
* HFrEF: LVEF \< 40 % in keeping with guideline-defined systolic HF.
Exclusion Criteria
2. Significant native or prosthetic valvular heart disease (moderate-to-severe) requiring surgery or trans-catheter therapy.
3. Congenital heart disease, hypertrophic cardiomyopathy, restrictive or constrictive pericardial pathology, or prior cardiac transplantation/LVAD.
4. Inadequate echocardiographic image quality (e.g., missing views, severe acoustic shadowing) precludes automated analysis.
5. Hemodynamic instability preventing standardized imaging or data collection.
6. Pregnancy.
7. Concurrent enrollment in another interventional trial that may confound results of imaging or biomarkers.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mackay Memorial Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chung-Lieh Hung
Director of Ultrasound Imaging and Telemedicine
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
25MMHIS019e
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.